Market Closed -
Nasdaq
04:30:00 2024-05-15 pm EDT
5-day change
1st Jan Change
6.24
USD
-3.85%
+9.86%
-4.00%
This article is reserved for members
Not a member ?
Free registration
Precipio, Inc. announced that it expects to receive $0.5 million in funding
Apr. 18
CI
Transcript : Precipio, Inc. - Special Call
Apr. 01
Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 29
CI
Precipio, Inc. and Cardinal Health Sign Distribution Agreement for Its HemeScreen®? Portfolio of Molecular Assays for Cancer
Feb. 06
CI
Sector Update: Health Care Stocks Slipping Late Afternoon
Jan. 17
MT
Sector Update: Health Care Stocks Edge Down Wednesday Afternoon
Jan. 17
MT
Precipio Signs Distribution Deal in Japan, Gets First Order; Shares Rise
Jan. 17
MT
Precipio, Inc. Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
Jan. 17
CI
Precipio, Inc. Announces Board Changes
Jan. 02
CI
Transcript : Precipio, Inc., Q3 2023 Earnings Call, Nov 20, 2023
Nov. 20
North American Morning Briefing : Stocks Futures -2-
Nov. 20
DJ
Precipio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Precipio, Inc. Reports Unaudited Revenue Results for the Third Quarter of 2023
23-10-18
CI
Precipio Says Lower Product Revenue Needed to Achieve Cash Flow Breakeven
23-09-25
MT
Precipio, Inc. Reports Unaudited Revenue Results for the August 2023
23-09-13
CI
Transcript : Precipio, Inc., Q2 2023 Earnings Call, Aug 17, 2023
23-08-17
Precipio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-11
CI
End in sight for U.S. insider trading case over healthcare leaks
23-08-01
RE
Precipio, Inc. Announces Unaudited Revenue Results for the Second Quarter of 2023
23-08-01
CI
Precipio's Omnia?? Methodology Enables Diagnosis of MDS with Peripheral Blood Instead of Bone Marrow Biopsy
23-06-14
CI
Precipio, Inc. Enters into Collaboration with Prestigious New York-Based Institution to Develop Revolutionary Brain Tumor Panel Using Hemescreen Technology
23-06-13
CI
Precipio Prices $2 Million Registered Direct Offering, Concurrent Private Placement
23-06-08
MT
Precipio, Inc. announced that it expects to receive $0.014343 million in funding
23-06-06
CI
Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
23-05-22
CI
Transcript : Precipio, Inc., Q1 2023 Earnings Call, May 17, 2023
23-05-17
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**